Company: ICUI
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0000883984-25-000016
Chunk: 106

Company: ICU MEDICAL INC/DE
Filing Date: 2025-05-08
Form: 10-Q
Item: Item 8
Chunk 106
---
 the maturities of our operating and finance lease liabilities for each of the next five years and thereafter are approximately (in thousands):Operating LeasesFinance LeasesRemainder of 2025$12,458 $833 202614,040 1,280 202711,444 920 20288,920 549 20297,254 204 20304,115 48 Thereafter14,256 — Total Lease Payments72,487 3,834 Less imputed interest(10,781)(364)Total$61,706 $3,470 

Note 8:    Net Loss Per Share

 Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is computed by dividing net loss income by the weighted-average number of common shares outstanding during the period plus dilutive securities. Dilutive securities include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options and restricted stock units that are anti-dilutive are not included in the treasury stock method calculation. A net loss for the three months ended March 31, 2025 and 2024, causes all of the potentially dilutive common shares to be antidilutive, and accordingly, they were not included in the computation of diluted earnings per share and basic and diluted net loss per share are equal for each of these periods.    The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data):   Three months ended March 31, 20252024Net loss$(15,476)$(39,471)Weighted-average number of common shares outstanding (basic)24,539 24,222 Dilutive securities(1)— — Weighted-average common and common equivalent shares outstanding (diluted)24,539 24,222 EPS — basic$(0.63)$(1.63)EPS — diluted$(0.63)$(1.63)Total anti-dilutive stock options and restricted stock awards40576_______________________________(1)    Due to the net loss for the three months ended March 31, 2025 and 2024, there are no potentially dilutive common shares included in the computation of diluted earnings per share